Engineered immune cells target and destroy glioblastoma in animal models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Until now, all available treatments, including immunotherapy—which involves strengthening the immune system to fight cancer—have…

Continue Reading

News Source: medicalxpress.com